Overview of Taris GemRIS, a Novel Drug Delivery System for Bladder Cancer

GemRIS, an implantable drug delivery system from Taris Biomedical that delivers continuous intravesical gemcitabine, shows potential for use in multiple bladder cancer settings. Ongoing and recently completed phase 1 trials in non–muscle-invasive as well as muscle-invasive bladder cancer are yieldin...

Full description

Saved in:
Bibliographic Details
Published in:European urology focus 2020-07, Vol.6 (4), p.620-622
Main Authors: Grimberg, Dominic C., Shah, Ankeet, Inman, Brant A.
Format: Article
Language:English
Subjects:
Antimetabolites, Antineoplastic - administration & dosage
Deoxycytidine - administration & dosage
Deoxycytidine - analogs & derivatives
Drug Delivery Systems
Humans
Urinary Bladder Neoplasms - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:GemRIS, an implantable drug delivery system from Taris Biomedical that delivers continuous intravesical gemcitabine, shows potential for use in multiple bladder cancer settings. Ongoing and recently completed phase 1 trials in non–muscle-invasive as well as muscle-invasive bladder cancer are yielding promising preliminary results.
ISSN:2405-4569
2405-4569
DOI:10.1016/j.euf.2019.09.006